Benjamin Edwards’s Intellia Therapeutics NTLA Stock Holding History
Bought
Maintained
Sold
Other funds holding NTLA
Benjamin Edwards's NTLA Position: Q3 2026 in Review
Benjamin Edwards increased its Intellia Therapeutics (NTLA) stake by 7.7% in Q3 2026, buying an estimated $77.6K and bringing the position to 87,085 shares worth $1.05M. The position accounts for 0.01% of the portfolio, ranked #792.
Benjamin Edwards first reported a position in NTLA in Q1 2019 and has held it in 31 quarters since. The position peaked at $1.37M in Q2 2026. 239 funds tracked by Wall St. Rank hold NTLA as of Q3 2026.
- Benjamin Edwards held 87,085 shares of Intellia Therapeutics worth $1.05M as of Q3 2026.
- Benjamin Edwards bought 6,204 Intellia Therapeutics shares in Q3 2026, an estimated $77.6K.
- Intellia Therapeutics made up 0.01% of Benjamin Edwards's portfolio in Q3 2026, its #792 holding.
- Benjamin Edwards first reported a position in Intellia Therapeutics in Q1 2019 and has held it in 31 quarters since.
- Benjamin Edwards's Intellia Therapeutics position peaked at $1.37M in Q2 2026.
- 239 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2026.
Based on Benjamin Edwards's 13F filing for Q3 2026, filed 12 Nov 2026.